Organon Aims to Start a Global Conversation Around Unplanned Pregnancy | Your money
JERSEY CITY, NJ – (BUSINESS WIRE) – Sep 21, 2021–
Organon (NYSE: OGN), a global women’s health company, is launching a Public Service Announcement (PSA) that aims to raise awareness and start a global conversation about the staggering rates of unintended pregnancy around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005986/en/
Globally, unplanned pregnancies affect an estimated 121 million women each year. 1 A 2019 study reported that around the world, over 1 billion women need family planning, but for 270 million of them, the need for modern family planning methods is unmet. 2 ** An unplanned pregnancy can affect any woman anywhere, regardless of her social or economic background.
“Although we have seen a lot of progress in reproductive health, rates of unintended pregnancies around the world remain high,” said Dr Sandy Milligan, MD, JD, head of research and development at Organon. “There is no better time than before World Contraception Day to focus on empowering women through education, information, empathy and conversation to help reduce unregulated pregnancies. planned. “
Organon invites women, their families, healthcare professionals and policy makers to visit https://hereforherhealth.com/unplanned/ to share their views on how to help reduce rates of unplanned pregnancies and join us in a collective mission to have the conversation.
“Now more than ever, it is essential to focus on the reproductive well-being of all,” said Dr Raegan McDonald-Mosley, MD, CEO of Power to Decide. “On World Contraception Day, we have a unique opportunity to highlight the importance of ensuring that all people – regardless of who they are, where they live or their economic situation – have the opportunity to decide whether , when and under what circumstances to get pregnant or have a child.
The PSA will air in local television and radio markets across the United States, be distributed on social media through a variety of channels and global partners, and is available at https: // hereforherhealth.com/unplanned/ where people are encouraged to share their views. on how to help reduce unplanned pregnancies.
Organon is a global healthcare company formed by a spin-off of Merck, known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. . Here for its health, the company has a portfolio of more than 60 drugs and products in a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and a stable established drug franchise, Organon’s products generate strong cash flow that will support investments in future growth opportunities in the field of women’s health, including business development such as the recent acquisition of Alydia Health, a medical device company focused on postpartum hemorrhage. In addition, Organon is seeking opportunities to collaborate with biopharmaceutical innovators who seek to commercialize their products by leveraging its scale and presence in rapidly growing international markets.
Organon has a global presence with significant scale and geographic reach, world-class business capabilities and approximately 9,000 employees headquartered in Jersey City, New Jersey.
For more information, visit https://www.organon.com/ and connect with us on LinkedIn and Instagram.
Organon’s forward-looking statement
Except for historical information contained herein, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, including but not limited to limit, to statements on the expectations of the management concerning the future prospects of Organon. . Forward-looking statements may be identified by words such as “objectives”, “potential”, “expects”, “intends”, “plans”, “plans”, “believes”, “seeks”, ” esteem “,” “or words with similar meanings. These statements are based on the current beliefs and expectations of the management of Organon and are subject to significant risks and uncertainties. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including fluctuations in interest rates and exchange rates; the impact of the current COVID-19 pandemic and the emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and globally; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; Organon’s ability to accurately predict future results and financial performance; Organon’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Organon’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions.
Organon assumes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in forward-looking statements can be found in the documents filed by Organon with the Securities and Exchange Commission (“SEC”), including its registration statement on Form 10, available on the SEC website. (www.sec.gov).
1 Bearak J, Painchalk A, Ganatra B, et al. Unintended pregnancies and abortion by income, region and legal status of abortion: estimates from a full model for 1990-2019. Lancet Glob Health. 2020; 8 (9): e1152-e1161. doi: 10.1016 / S2214-109X (20) 30315-6
2 Kantorová V, Wheldon MC, Ueffing P, Dasgupta ANZ (2020) Estimating Progress Towards Meeting Women’s Contraceptive Needs in 185 Countries: A Bayesian Hierarchical Modeling Study. PLoS Med 17 (2): e1003026. https://doi.org/10.1371/journal.pmed.1003026
** According to Kantorová et. All modern methods of contraception include female and male sterilization, intrauterine device (IUD), implant, injectables, oral contraceptive pills, male and female condoms, vaginal barrier methods, the method of birth control. breastfeeding and amenorrhea (LAM), emergency contraception and other modern methods of contraception. methods such as the contraceptive patch or vaginal ring.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210920005986/en/
CONTACT: Media contacts:
(614) 314-8094 Kate Vossen
(732) 675-8448 Investor contacts:
(201) 275-2711 Edward Barger
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: MEDICAL DEVICES WOMEN BIOTECHNOLOGY OTHER HEALTH CARE CONSUMER HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Organon & Co.
Copyright Business Wire 2021.
PUB: 09/21/2021 12:01 a.m. / DISC: 09/21/2021 12:01 a.m.